Relay Therapeutics (RLAY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
BenzingaSep 9 06:56 ET
Goldman Sachs Upgrades Relay Therapeutics(RLAY.US) to Buy Rating, Announces Target Price $20
Moomoo News17:31 ET · Ratings
Express News | Relay Therapeutics Announces Proposed Public Offering of Common Stock
Reuters16:34 ET
Top Midday Gainers
MT Newswires13:58 ET
Relay Stock Rallies 41% on Positive Data for RLY-2608
Seeking AlphaSep 9 10:39 ET
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
BenzingaSep 9 10:13 ET

Comments

Newbee4

1 hour ago

$20

$Relay Therapeutics (RLAY.US)$

Goldman Sachs Upgrades Relay Therapeutics(RLAY.US) to Buy Rating, Announces Target Price $20

1

Trytosaveabit

4 hours ago

OFFERING

$Relay Therapeutics (RLAY.US)$ CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.(NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an add...

1

6

jimmy the trader

11 hours ago

Sweet potato

$Relay Therapeutics (RLAY.US)$

1

Trytosaveabit

14 hours ago

$Relay Therapeutics (RLAY.US)$ Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse...

3

1

Jaguar8

14 hours ago

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Relay Therapeutics announced positive interim data for RLY-2608, a pan-mutant and isoform-selective inhibitor of PI3Kα, in treating PI3Kα-mutated, HR+/HER2- metastatic breast cancer. Key findings include:
- 9.2-month median progression-free survival (PFS) in heavily pre-treated patients at the recommended Phase 2 dose (RP2D)
- 33% overal...

RLAY Relay Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target